HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?

被引:28
|
作者
Husereau, Don [1 ]
Marshall, Deborah A. [2 ]
Levy, Adrian R. [3 ]
Peacock, Stuart [4 ]
Hoch, Jeffrey S. [5 ]
机构
[1] Univ Ottawa, Univ Hlth Sci Med Informat & Technol, Inst Hlth Econ, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada
[2] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 4Z6, Canada
[3] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS B3H 1V7, Canada
[4] Univ British Columbia, Canadian Ctr Applied Res Canc Control, British Columbia Canc Res Ctr, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada
[5] Canadian Ctr Appl Res Canc Control, Pharmacoecon Res Unit, Canc Care Ontario, Toronto, ON M5G 2L7, Canada
关键词
Costs and cost analysis; Biomedical research/methods; Biomedical research/standards; Decision support techniques; Delivery of health care; Diagnostic techniques and procedures; Health policy; Humans; Individualized medicine/methods; Technology assessment; Biomedical; COST-EFFECTIVENESS ANALYSIS; BREAST-CANCER; HETEROGENEITY; FRAMEWORK; TESTS; WOMEN;
D O I
10.1017/S0266462314000142
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Many jurisdictions delivering health care, including Canada, have developed guidance for conducting economic evaluation, often in the service of larger health technology assessment (HTA) and reimbursement processes. Like any health intervention, personalized medical (PM) interventions have costs and consequences that must be considered by reimbursement authorities with limited resources. However, current approaches to economic evaluation to support decision making have been largely developed from population-based approaches to therapy-that is, evaluating the costs and consequences of single interventions across single populations. This raises the issue as to whether these methods, as they are or more refined, are adequate to address more targeted approaches to therapy, or whether a new paradigm for assessing value in PM is required. Objectives: We describe specific issues relevant to the economic evaluation of diagnostics-based PM and assess whether current guidance for economic evaluation is sufficient to support decision making for PM interventions. Methods: Issues were identified through literature review and informal interviews with national and international experts (n = 10) in these analyses. This article elaborates on findings and discussion at a workshop held in Ottawa, Canada, in January 2012. Results: Specific issues related to better guiding economic evaluation of personalized medicine interventions include: how study questions are developed, populations are characterized, comparators are defined, effectiveness is evaluated, outcomes are valued and how resources are measured. Diagnostics-based PM also highlights the need for analyses outside of economic evaluation to support decision making. Conclusions: The consensus of this group of experts is that the economic evaluation of diagnostics-based PM may not require a new paradigm. However, greater complexity means that existing approaches and tools may require improvement to undertake these more analyses.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [1] Economic Evaluation of Environmental Health Interventions to Support Decision Making
    Hutton, Guy
    ENVIRONMENTAL HEALTH INSIGHTS, 2008, 2 : 137 - 155
  • [2] Cognitive evaluation of decision making processes and assessment of information technology in medicine
    Kushniruk, Andre W.
    Patel, Vimla L.
    International Journal of Medical Informatics, 51 (2-3): : 83 - 90
  • [3] Cognitive evaluation of decision making processes and assessment of information technology in medicine
    Kushniruk, AW
    Patel, VL
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 1998, 51 (2-3) : 83 - 90
  • [4] Health technology assessment and economic evaluation: Is it applicable for the traditional medicine?
    Chen, Yingyao
    INTEGRATIVE MEDICINE RESEARCH, 2022, 11 (01)
  • [5] Economic analysis to support remedial decision making and technology selection
    Hardisty, PE
    Brown, A
    PHYTOREMEDIATION AND INNOVATIVE STRATEGIES FOR SPECIALIZED REMEDIAL APPLICATIONS, 1999, : 289 - 294
  • [6] Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries
    Zisis, Konstantinos
    Naoum, Panagiota
    Athanasakis, Kostas
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 37 (01)
  • [7] DIGITAL HEALTH INTERVENTIONS: A REVIEW OF ECONOMIC EVALUATION GUIDELINES FROM HEALTH TECHNOLOGY ASSESSMENT AGENCIES
    Zhou, A.
    Yi, Y.
    VALUE IN HEALTH, 2022, 25 (12) : S301 - S302
  • [8] Health Technology Assessment and Private Payers' Coverage of Personalized Medicine
    Trosman, Julia R.
    Van Bebber, Stephanie L.
    Phillips, Kathryn A.
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (03) : 18S - 24S
  • [9] Health Technology Assessment and Private Payers' Coverage of Personalized Medicine
    Trosman, Julia R.
    Van Bebber, Stephanie L.
    Phillips, Kathryn A.
    AMERICAN JOURNAL OF MANAGED CARE, 2011, 17 (05): : SP53 - SP60
  • [10] Economic evaluation enhances public health decision making
    Rabarison, Kristina M.
    Bish, Connie L.
    Massoudi, Mehran S.
    Giles, Wayne H.
    FRONTIERS IN PUBLIC HEALTH, 2015, 3